Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth
Texas
76134
United States
Tel: 800-451-3937-or-817-293-0450
Fax: 817-551-4615
Website: http://www.alconinc.com/
115 articles about Alcon Laboratories, Inc.
-
Alcon CEO says the company is "poised to achieve sustainable growth and create long-term shareholder value as a standalone company."
-
Alcon will officially step out from under the Novartis umbrella on April 9 as it will trade on the NYSE and the SIX Swiss Exchange.
-
Alcon said the acquisition of PowerVision demonstrates its commitment to bringing advanced technology intraocular lenses to cataract patients across the globe.
-
BioSpace Movers and Shakers Nov. 5
11/5/2018
Biopharma companies make key appointments to fill leadership positions. Let's take a look! -
According to Jay Bradner, president of the Novartis Institutes for Biomedical Research, the company is cutting its drug programs from 430 to 340. One of the big areas the company is abandoning is infectious diseases. The decision is a result of a strategic review by Vasant (Vas) Narasimhan, the c...
-
Amidst Strong Quarterly Growth, Novartis Receives FDA Complete Response Letter for Canakinumab
10/18/2018
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration for canakinumab as a potential treatment for cardiovascular ris... -
Swiss pharmaceutical giant Novartis plans to slash approximately 2,200 jobs in Switzerland over the next four years.
-
Alcon, the Novartis eye care business, is leaving its longtime home of Texas for Switzerland. The company said it will move its corporate headquarters from Fort Worth to Geneva following the spinoff from Novartis.
-
Today Narasimhan and Novartis announced they were selling U.S. dermatology and generic drug assets, parts of its Sandoz division, to India’s Aurobindo Pharma for up to $1 billion. The deal includes approximately 300 products.
-
Biotech Movers and Shakers Aug. 27
8/27/2018
Who made a splash in the biotech world this week? Here are some notable people. -
Eyevensys Appoints New Board Member, Gerald Cagle
8/9/2018
– Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced that Gerald (Jerry) Cagle, Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories has joined its Board of Directors.
-
As Novartis locks in on a $13 billion deal with GlaxoSmithKline (GSK), Novartis chief executive officer Vasant Narasimhan confirms that any decision about spinning off its Alcon eye care business won’t be made until the first half of 2019.
-
Alcon Release: New Data Shows Astigmatism Tends To Worsen Following Cataract Surgery With A Standard Monofocal IOL, While Patient Awareness About Advanced Technology Treatment Options Is Limited
10/11/2017
-
Alcon Receives CE Mark For First-Of-Its-Kind Autonome Preloaded Intraocular Lens (IOL) Delivery System With Clareon IOL
10/6/2017
-
Argentum Succeeds In Starting Patent Cancellation Trial Against Alcon's TRAVATAN Z
10/2/2017
-
Alcon Introduces New Innovations In Cataract Surgery At European Society Of Cataract & Refractive Surgeons 2017 Annual Congress
10/2/2017
-
Alcon DAILIES Teams Up With U.S. Olympians - World-Class Gymnast Laurie Hernandez And Soccer Star Tobin Heath - To Launch The Invisible Edge Campaign
9/25/2017
-
Aerie Poaches Another Exec From Novartis AG' Tormented Alcon Biz
9/19/2017
-
Novartis AG's Long-Suffering Alcon Sees Sales Growth in Q2, Opening Door to Spin-Off IPO
7/18/2017
-
Dr. Stephen S. Lane Joins Alcon As Chief Medical Officer And Global Head Franchise Clinical Strategy
5/9/2017